subscribe
Latest News
Keep up-to-date with BMS Canada
-
MONTREAL, QUEBEC – January 14, 2013
ERBITUX® IN COMBINATION WITH CHEMOTHERAPY APPROVED IN CANADA AS INITIAL TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
First new biologic treatment regimen approved in eight years for newly diagnosed patients with metastatic colorectal cancerCategories: Erbitux | Metastatic colorectal cancer | Public Communication | Public Notices
-
Montreal, QC - December 6, 2012
ONE-IN-FOUR CANADIANS OVER 40 WILL SUFFER FROM ATRIAL FIBRILLATION IN THEIR LIFE TIME
Health Canada Approves Eliquis™, a New Oral Anticoagulant, for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation Increased risk of stroke is one of the most serious medical concerns for people with atrial fibrillation. The condition increases a person’s risk of stroke up to five times.Categories: Eliquis | Public Communication | Public Notices
-
MONTREAL, QUEBEC - September 18, 2012
ONTARIO AND SASKATCHEWAN BECOME FIRST PROVINCES TO PROVIDE ACCESS TO INNOVATIVE AND POTENTIALLY LIFE-EXTENDING IMMUNOTHERAPY YERVOY FOR PREVIOUSLY TREATED METASTATIC MELANOMA PATIENTS
Positive multi-province dialogue promises new hope for Canadians with metastatic melanomaCategories: Public Communication | Public Notices | Yervoy
Expanded Access Programs
Expanded Access Programs
Expanded Access, Named Patient and Emergency Use Programs for Bristol-Myers Squibb Medicines. Find out more.
Community
Events & Programs
BMS Canada is committed to community involvement. Find out more.
Careers
Looking for a Great Career?
Bristol-Myers Squibb Canada can offer you the challenge and support you are looking for in a friendly, motivating and exciting atmosphere. Find out more.